RESUMEN
Caso clínico: Mujer en el sexto mes de gestación, con antecedentes de cirugía refractiva, que consulta por metamorfopsias y disminución de la agudeza visual en el ojo derecho. En la exploración se observa una membrana neovascular coroidea subfoveal asociada al síndrome de presunta histoplasmosis ocular (SPHO). Tras el parto se realiza tratamiento con dos dosis mensuales de bevacizumab intravítreo. La tercera dosis no se realiza por nuevo embarazo, observándose posteriormente aborto espontáneo sin causa conocida. Discusión: El tratamiento con bevacizumab intravítreo durante el embarazo es controvertido, ya que es posible que aumente el riesgo del aborto espontáneo durante el primer trimestre(AU)
Clinical case: Female in her sixth month of pregnancy, with a history of refractive surgery, who consulted due to a metamorphopsia and decrease in visual acuity in the right eye. A presumed ocular histoplasmosis syndrome (POHS) and a subfoveal choroidal neovascular membrane were observed in the fundoscopy. Two monthly doses of intravitreal bevacizumab were given after the labour, but the third dose was never inyected as the patient became pregnant again. She subsequently had a spontaneous miscarriage. Discussion: Treatment with intravitreal bevacizumab during pregnancy is controversial as it may increase the risk of miscarriage during the first trimester(AU)
Asunto(s)
Humanos , Femenino , Embarazo , Inyecciones Intravítreas , Neovascularización Coroidal , Aborto Espontáneo , Embarazo , Informes de CasosRESUMEN
CLINICAL CASE: Female in her sixth month of pregnancy, with a history of refractive surgery, who consulted due to a metamorphopsia and decrease in visual acuity in the right eye. A presumed ocular histoplasmosis syndrome (POHS) and a subfoveal choroidal neovascular membrane were observed in the fundoscopy. Two monthly doses of intravitreal bevacizumab were given after the labour, but the third dose was never inyected as the patient became pregnant again. She subsequently had a spontaneous miscarriage. DISCUSSION: Treatment with intravitreal bevacizumab during pregnancy is controversial as it may increase the risk of miscarriage during the first trimester.